TCGA-AR-A250-01A-31R-A169-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 90
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- ANGIOGENESIS+0.450
- INTERFERON_ALPHA_RESPONSE+0.390
- INTERFERON_GAMMA_RESPONSE+0.390
- TGF_BETA_SIGNALING+0.390
- ANDROGEN_RESPONSE+0.380
- G2M_CHECKPOINT+0.380
- PROTEIN_SECRETION+0.350
- MITOTIC_SPINDLE+0.330
- NOTCH_SIGNALING+0.330
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- OXIDATIVE_PHOSPHORYLATION-0.280
- KRAS_SIGNALING_DN-0.240
- UV_RESPONSE_UP-0.210
- HEME_METABOLISM-0.160
- PANCREAS_BETA_CELLS-0.150
- WNT_BETA_CATENIN_SIGNALING-0.120
- BILE_ACID_METABOLISM-0.100
- ADIPOGENESIS-0.070
- FATTY_ACID_METABOLISM-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A07I-01A-11R-A00Z-07 | — | C | 0.862 |
| 2 | TCGA-FD-A62S-01A-11R-A30C-07 | — | — | 0.856 |
| 3 | TCGA-55-6978-01A-11R-1949-07 | — | cohortA1 | 0.843 |
| 4 | SRR934886 | — | — | 0.833 |
| 5 | TCGA-66-2788-01A-01R-0980-07 | — | cohortSQ1 | 0.828 |
| 6 | MDT-AP-3337 | Med | Medulloblastoma | 0.826 |
| 7 | SRR934737 | — | — | 0.817 |
| 8 | TCGA-CQ-5334-01A-01R-1686-07 | — | — | 0.813 |
| 9 | TCGA-FD-A6TK-01A-42R-A33J-07 | — | — | 0.807 |
| 10 | TCGA-44-7661-01A-11R-2066-07 | — | cohortA1 | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.260 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |